ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
16 announcements with these filters
Sandu Pharmaceuticals scheduled a board meeting on November 14, 2026, to approve unaudited financial results. The meeting covers the quarter and half-year ended September 30, 2026.
The company submitted its quarterly shareholding pattern under Regulation 31(1)(b) for the quarter ended September 30, 2026.
Sandu Pharmaceuticals intimated that Non-Executive Independent Director Dr Neeti Madan Kapre has changed her name to Dr Neeti Gupta after marriage. The DIN, designation and directorship remain unchanged.
Sandu Pharmaceuticals Limited has issued a reminder to physical shareholders regarding the mandatory submission of PAN and KYC details. This compliance follow-up aims to facilitate electronic dividend payments.
Sandu Pharmaceuticals appointed Dr. Neeti Madan Kapre as director and Dave & Dave as statutory auditor, while announcing other board and auditor tenure changes.
Sandu Pharmaceuticals has appointed M/s. Dave & Dave as Statutory Auditors for a five-year term, following the tenure expiry of the previous auditors.
Sandu Pharmaceuticals Limited held its 41st Annual General Meeting on September 11, 2026, via video conferencing to transact ordinary and special business items.
Sandu Pharmaceuticals Ltd issued a letter to shareholders whose email addresses are not registered, providing the weblink to the Annual Report for FY 2026-27.
Sandu Pharmaceuticals Limited has filed its 41st Annual Report for the financial year 2025-26, including the notice for the upcoming 41st Annual General Meeting.
Sandu Pharmaceuticals announced its 41st Annual General Meeting scheduled for September 11, 2026. The notice includes resolutions for dividend declaration and board appointments.
Sandu Pharmaceuticals Limited filed its quarterly Statement of Deviation or Variation in utilization of funds for the quarter ended June 30, 2026. No deviation or variation was reported.
Sandu Pharmaceuticals Ltd reported revenue from operations of ₹16.4 Cr (-1.8% YoY) and net profit of ₹0.2 Cr (+0.0% YoY) for Q1 FY27.
Sandu Pharmaceuticals scheduled a Board Meeting for August 11, 2026. The meeting will consider the standalone unaudited financial results for the quarter ended June 30, 2026.
Sandu Pharmaceuticals announced the demise of MD Shri Umesh B. Sandu. Consequently, Shri Balram Viswanathan was redesignated as Chairman and MD, and Dr. Neeti Kapre was appointed Independent Director.
Sandu Pharmaceuticals will hold a board meeting on 11 July 2026 to record the MD’s demise and appoint a Managing Director. Trading window is closed for directors.
Sandu Pharmaceuticals filed its Annual Secretarial Compliance Report for the year ended March 2026. The auditor confirmed general regulatory compliance with minor previous reporting delays noted.